Elmind Capital LP Takes Position in Alumis Inc. $ALMS

Elmind Capital LP acquired a new stake in shares of Alumis Inc. (NASDAQ:ALMS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 130,000 shares of the company’s stock, valued at approximately $3,658,200,000. Alumis comprises about 0.9% of Elmind Capital LP’s investment portfolio, making the stock its 24th biggest position. Elmind Capital LP owned about 0.10% of Alumis at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after purchasing an additional 4,894 shares in the last quarter. New York State Common Retirement Fund raised its position in Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after buying an additional 7,467 shares during the last quarter. KBC Group NV bought a new position in Alumis during the 1st quarter valued at about $42,000. Strs Ohio grew its stake in shares of Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares during the period.

Insiders Place Their Bets

In other Alumis news, insider Mark Christopher Bradley sold 2,572 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $67,823.64. Following the completion of the sale, the insider owned 48,533 shares of the company’s stock, valued at $1,279,815.21. This trade represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Roy C. Hardiman sold 2,692 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $70,988.04. Following the completion of the sale, the insider owned 207,746 shares in the company, valued at approximately $5,478,262.02. The trade was a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 19,953 shares of company stock valued at $534,311. 33.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ALMS shares. Citigroup reiterated a “neutral” rating on shares of Alumis in a research report on Monday, August 17th. Wells Fargo & Company raised their price objective on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Wall Street Zen upgraded shares of Alumis from a “strong sell” rating to a “hold” rating in a research report on Sunday. Morgan Stanley restated an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research report on Friday, May 15th. Finally, Chardan Capital boosted their price objective on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $40.30.

Alumis Stock Up 4.0%

NASDAQ ALMS opened at $23.96 on Wednesday. Alumis Inc. has a twelve month low of $3.76 and a twelve month high of $31.35. The business has a 50-day moving average price of $26.57 and a 200-day moving average price of $25.15. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -6.21 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The business had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. Research analysts expect that Alumis Inc. will post -2.95 EPS for the current fiscal year.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.